You searched for "intravitreal"
ROP anti-VEGF treatment review
The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...
Posterior capsular rupture risk factors as reported in the European registry
In this cross-sectional review of the European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO) including 2,853,376 patients and 31,749 cases with posterior capsular rupture (PCR), the authors observed a trend of reduction in PCR rate from 1.44%...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Adjunct amniotic membrane during enucleation for retinoblastoma to prevent implant exposure
28 February 2025
| Fiona Rowe (Prof)
|
EYE - Paediatrics
Amniotic membrane (AM) has potential for treatment of retinoblastoma (RB) patients with contracted sockets after enucleation. The authors present their experience of AM with enucleation for patients with RB after chemotherapy in this retrospective study of 100 eyes of 107...
A case of ‘60-day glaucoma’
3 April 2023
| Jagruti Godhaniya, Rajan Paul
|
EYE - General
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...
Vitreomacular traction: natural course vs. vitrectomy vs. ocriplasmin
3 June 2024
| Haider Manzar
|
EYE - Vitreo-Retinal
Over time, the vitreous gel completely separates from the retina in a process known as a posterior vitreous detachment (PVD). In some instances, however, the vitreous does not detach entirely and remains adherent to the macula. The term vitreomacular traction...
In conversation with Salman Waqar
1 December 2018
| Salman Waqar, Hari Kaneshayogan
|
EYE - General
Hari Kaneshayogan interviews Salman Waqar, a Consultant Ophthalmologist with a keen interest in medical innovation. He is the inventor of the Waqar suture removal forceps, which combines suture cut and removal in one instrument. He has also created an injection...
Initiatives in macular service provision
1 December 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
Insights from the ‘Rb-NET Challenges’ Session: Evolving approaches in global retinoblastoma management
2 April 2025
| Mattan Arazi, Ido Didi Fabian, Nick Astbury, Brenda Gallie (Prof), Covadonga Bascaran, Marcia Zondervan
|
EYE - Paediatrics, EYE - Pathology, EYE - Oncology
The Retinoblastoma Network (Rb-NET) Multidisciplinary Team (MDT) platform, developed by the London School of Hygiene & Tropical Medicine (LSHTM) and Professor Ido Didi Fabian, is a web-based telemedicine initiative that regularly hosts virtual MDT meetings focused on the evaluation and...
Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments
1 February 2017
| Manoj V Parulekar
|
EYE - Oncology
Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...
Do patient demographics influence AMD clinic attendance during COVID-19 lockdown?
3 June 2021
| Kumarapaksha Mohottalage Bhagya Mekhalani Weerasinghe, Jai Shankar
|
EYE - Vitreo-Retinal
The authors assess the impact of the COVID-19 pandemic on adherence to scheduled clinic appointments among age-related macular degeneration patients in a clinic in North Wales. The COVID-19 pandemic has significantly affected the population, affecting economic and social wellbeing, whilst...
Resolution of mid-peripheral schisis in x-linked retinoschisis with the use of dorzolamide
1 October 2014
| Huw Edward Oliphant
|
EYE - Vitreo-Retinal
X-linked retinoschisis (XLRS) is an early onset hereditary retinal dystrophy. It is caused by mutations of the RS1 gene. Common manifestations of XLRS are schitic lesions at the macula, as well as infero-temporal schisis. Carbonic anhydrase inhibitors have previously been...
